AbbVievsAlnylam Pharmaceuticals

ABBV and ALNY stock compared: price, dividend, valuation and results, from SEC filings.

ALNY

Alnylam Pharmaceuticals, Inc.

$154.31

Value $20.5B

-1.28%
ALNY's page

AbbVie (ABBV) has a market value of $512B and Alnylam Pharmaceuticals (ALNY) $20.5B. Over the last year, with dividends, ABBV moved +27.5% and ALNY -66.5%. Dividend yield: ABBV 2.39%, ALNY none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ABBV$512B

    ALNY$20.5B

    ABBV is 25 times ALNY

  • Revenue, 12 months

    ABBV$66.0B

    ALNY$5.0B

    ABBV is 13 times ALNY

  • Net income, 12 months

    ABBV$10.3B

    ALNY$2.6B

    ABBV is 3.9 times ALNY

  • Operating margin

    ABBV32.2%

    ALNY19.5%

    12.7 points apart

  • ROIC

    ABBV25.7%

    ALNY31.8%

    6.1 points apart

  • P/E

    ABBV49.8

    ALNY–

  • Dividend yield

    ABBV2.4%

    ALNY0.0%

    2.4 points apart

  • 5-year return

    ABBV+195.1%

    ALNY-10.7%

    205.8 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ABBV+195.1%

ALNY-10.7%

10020030020222023202420252026
Returns by period
PeriodABBVWith dividendsALNYWith dividends
1 year since November 17, 2025+27.5%Price +23.8%-66.5%Price -66.5%
3 years since November 17, 2023+131.6%+32.3% a yearPrice +109.5%-5.8%-2.0% a yearPrice -5.8%
5 years since November 17, 2021+195.1%+24.2% a yearPrice +146.9%-10.7%-2.2% a yearPrice -10.7%
10 years since November 18, 2016+619.6%+21.8% a yearPrice +378.7%+235.6%+12.9% a yearPrice +235.6%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ABBVAbbVieALNYAlnylam Pharmaceuticals

Valuation

ABBVALNY
Valuation
Price$289.70$154.31
Market value$512B$20.5B
Enterprise value (EV)$582B–
P/E49.8–
P/E, 5-year median57.0–
P/B–5.7
EV/EBIT27.4–
Free cash flow yield3.7%3.9%

Results and growth

ABBVALNY
Results and growth
Revenue, 12 months$66.0B$5.0B
Net income, 12 months$10.3B$2.6B
Free cash flow, 12 months$18.9B$806M
Earnings per share, 12 months$5.81$19.98
Revenue growth, year on year8.6%65.2%
Revenue growth a year, past+5.9%over 5 years+49.8%over 5 years
EPS growth a year, past-2.8%over 5 years–

Margins and returns on capital

ABBVALNY
Margins and returns on capital
Gross margin73.7%77.4%
Operating margin32.2%19.5%
Net margin15.7%52.8%
ROIC25.7%31.8%
ROE–178.9%

Balance sheet

ABBVALNY
Balance sheet
Cash$10.8B$3.6B
Total debt$80.9B–
Net debt / EBITDA3.2–
Interest cover7.1×3.3×

Dividends and buybacks

ABBVALNY
Dividends and buybacks
Dividend yield2.4%–
Dividend per share, 12 months$6.92–
Dividend growth a year, past+6.6%over 5 years–
Buyback yield0.2%–
Shareholder yield2.6%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ABBV or ALNY

Didn't find what you were looking for?

Ask us
Which is bigger, AbbVie or Alnylam Pharmaceuticals?

By market value, AbbVie ($512B) is about 25.0 times Alnylam Pharmaceuticals ($20.5B), at today's prices.

How did ABBV and ALNY stock do over the last 10 years?

Since November 18, 2016, ABBV's price moved +378.7% and ALNY's +235.6%. With dividends: ABBV +619.6% (+21.8% a year), ALNY +235.6% (+12.9% a year). Past returns do not predict future ones.

Which pays the higher dividend, ABBV or ALNY?

The dividend yield at today's price is 2.39% for AbbVie and none for Alnylam Pharmaceuticals. Over the last twelve months they paid $6.92 and – per share.

Which has the higher profit margins, AbbVie or Alnylam Pharmaceuticals?

Over the last twelve months, the net margin was 15.7% for AbbVie and 52.8% for Alnylam Pharmaceuticals, and the operating margin 32.2% and 19.5%. Revenue was $66.0B and $5.0B.

Which is the better investment, AbbVie or Alnylam Pharmaceuticals?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.